Cost-Effectiveness Analysis of Gemtuzumab Ozogamicin for First-Line Treatment of Patients with Cd-33 Positive Acute Myeloid Leukaemia in Spain [Corrigendum]

• Prif Awduron: Mareque M (Awdur), Montesinos P (Awdur), Font P (Awdur), Guinea JM (Awdur), de la Fuente A (Awdur), Soto J (Awdur), Oyagüez I (Awdur), Brockbank J (Awdur), Iglesias T (Awdur), Llinares J (Awdur), Sierra J (Awdur)
• Fformat: Llyfr
• Cyhoeddwyd: Dove Medical Press, 2021-07-01T00:00:00Z.
• Pynciau: article
• Mynediad Ar-lein: Connect to this object online.

Mareque M, Montesinos P, Font P, et al. Clinicoecon Outcomes Res. 2021;13:263–277. Page 271, Results, Base Case, second line from the bottom, the text “€ 15,134” should read “€ 151,434”. The authors apologize for this error. Read the original article